ResearcherJiangsu UniversityNo recent work listed

Yawen Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8544-5006; OpenAlex author ID A5006485393. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. Co-author DOI 10.1155/2022/5361241 ↗
The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. Co-author DOI 10.1002/1878-0261.12836 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Aihua Gong · 2 shared papers, 2021–2022 · strength 0.28
- Paper Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. DOI 10.1155/2022/5361241 ↗
- Paper The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. DOI 10.1002/1878-0261.12836 ↗
Min Xu · 2 shared papers, 2021–2022 · strength 0.28
- Paper Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. DOI 10.1155/2022/5361241 ↗
- Paper The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. DOI 10.1002/1878-0261.12836 ↗
Youli Zhang · 1 shared paper, 2021 · strength 0.12
- Paper The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. DOI 10.1002/1878-0261.12836 ↗
Jingyu Min · 1 shared paper, 2021 · strength 0.12
- Paper The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. DOI 10.1002/1878-0261.12836 ↗
Huizhi Wang · 1 shared paper, 2021 · strength 0.12
- Paper The KRAS/Lin28B axis maintains stemness of pancreatic cancer cells via the let-7i/TET3 pathway. DOI 10.1002/1878-0261.12836 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.